Knowing what type of myeloma you are facing allows you to better fight it. High-risk genetic myeloma often requires a more aggressive treatment regimen than those who are standard-risk patients. Learn from Skyline Dx representatives about their new diagnostic test. This test is one way that newly diagnosed patients can discover their genetic risk and become more empowered to face it head on. Learn with us and come with your questions.

_{SkylineDx is a biotechnology company, focused on the research & development of molecular diagnostics in oncology and inflammatory diseases. The company is headquartered in Rotterdam (the Netherlands) and complemented with a field medical and scientific affairs team in the US and a CAP/CLIA certified laboratory in San Diego (California). SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of the disease or predict a patient’s response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient.}